Inhibitors of cellular metabolic processes

The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA):wherein RA, RB, RC, RD, and RE are defined herein.

Saved in:
Bibliographic Details
Main Authors Konteatis, Zenon D, Sui, Zhihua, Travins, Jeremy M, Ye, Zhixiong
Format Patent
LanguageEnglish
Published 23.04.2024
Subjects
ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA):wherein RA, RB, RC, RD, and RE are defined herein.
Bibliography:Application Number: US202217689209